Search Results

Terry Kenakin's "Applying Pharmacology to Drug Discovery" course at Dr. GPCR Partnered Events April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join the Endocrine Metabolic GPCRs event in Birmingham, UK, on April 22-23, 2024. and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April

GPCR University Course, ‘Applying Pharmacology to Drug Discovery,’ led by Dr. GPCR Partnered Events April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join the Endocrine Metabolic GPCRs event in Birmingham, UK, on April 22-23, 2024. Discovery of potential TAAR1 agonist targeting neurological and psychiatric disorders: An in silico approach 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April

evidence suggests that GPCRs also signal from intracellular membranes including endosomes, the Golgi apparatus In addition to endosomal signaling, GPCRs are also known to localize to the Golgi apparatus, where they pharmaceutical challenges associated with tagging GPCRs expressed in cellular compartments require innovative approaches

GPCR University Today marks the conclusion of the Dr.GPCR University course, ‘Applying Pharmacology to If you are interested in applying, please email us your CV/Resume at  Hello@DrGPCR.com. Dr. April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join Dr. GPCR Founder Dr. Yamina Berchiche at the Endocrine Metabolic GPCRs event in Birmingham, UK, on April 22-23, 2024. 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April

GPCR University course, 'Applying Pharmacology to Drug Discovery,' led by Dr. If you are interested in applying, please email us your CV/Resume at  Hello@DrGPCR.com. Dr. April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join Dr. GPCR founder Dr. Yamina Berchiche at the Endocrine Metabolic GPCRs event in Birmingham, UK, on April 22-23, 2024. 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April

GPCR University Last week marked the beginning of our first Dr.GPCR University course, 'Applying Pharmacology If you are interested in applying, please email us your CV/Resume at  Hello@DrGPCR.com. Dr. April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join our Founder Dr. Yamina Berchiche at the Endocrine Metabolic GPCRs event in Birmingham, UK, on April 22-23, 2024. 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April

GPCR University This week marks the beginning of our first Dr.GPCR University course, 'Applying Pharmacology If you are interested in applying, please email us your CV/Resume at  Hello@DrGPCR.com. Dr. April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join the Endocrine Metabolic GPCRs event in Birmingham , UK, on April 22-23, 2024. 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April

Xavier Leroy on his appointment as CEO of GIO Therapeutics! We appreciate your enthusiasm and interest in advancing your knowledge with us. If you are interested in applying, please email us your CV/Resume at  Hello@DrGPCR.com. Dr. Xavier Leroy appointed as CEO of GIO Therapeutics GPCR Events, Meetings, and Webinars NOW! 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April

GPCR University course, Applying Pharmacology to Drug Discovery, led by Dr. April 22 - 23, 2024 | Endocrine Metabolic GPCRs  Join Dr. GPCR at the Endocrine Metabolic GPCRs Summit on April 22-23, 2024, in Birmingham, UK. Dr. G protein Signaling 14 Ameliorates NAFLD through Activating cAMP-AMPK Signaling by Targeting Giα1/3 APOL1 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April

April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join us at the Endocrine Metabolic GPCRs event on April Unveils MolFlux: Empowering the ML Community in Molecular Predictive Modelling NanoImaging Services Appoints and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April

Congratulations to Domain Therapeutics for appointing Michael Gottlieb as Chairman and Dr. Potential Therapeutics for Psychiatric Disorders Structural and Molecular Insights into GPCR Function Apelin and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April 5 - 10, 2024 | AACR Annual Meeting April 22 - 23, 2024 | Endocrine Metabolic GPCRs May 13 - 17, 2024

chemosensory-related gene families in gastropods Unraveling the G protein-coupled receptor superfamily in aphids Morgan Healthcare Conference Andrew Hopkins appointed CBE by HM King Charles III Voyager Therapeutics and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April 5 - 10, 2024 | AACR Annual Meeting April 22 - 23, 2024 | Endocrine Metabolic GPCRs May 13 - 17, 2024

The therapeutic approaches mainly include small molecule inhibitors, as well as monoclonal antibodies The anti-CCR4 antibody mogamulizumab has also been approved in Japan and by the FDA for the treatment Therefore, an alternative approach is to make use of chemokine receptors redundancy and the fact that of administration are particularly rigorous for this class, as the majority of potential therapeutic applications

We appreciate your continued support and readership. with focus on the receptor-binding domain of SARS-CoV-2 Microscopy and spectroscopy approaches to study and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April 5 - 10, 2024 | AACR Annual Meeting April 22 - 23, 2024 | Endocrine Metabolic GPCRs May 13 - 17, 2024

Clinical Studies AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion FDA approves and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April 5 - 10, 2024 | AACR Annual Meeting April 22 - 23, 2024 | Endocrine Metabolic GPCRs May 13 - 17, 2024

GPCR somatostatin receptors 2 and 3 as cancer biomarkers beyond NET: a paired immunohistochemistry approach GPCR Research Modulating signalling lifetime to optimise a prototypical animal opsin for optogenetic applications and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April 5 - 10, 2024 | AACR Annual Meeting April 22 - 23, 2024 | Endocrine Metabolic GPCRs May 13 - 17, 2024

AlphaFold2-multimer models and interface interactions Experimental modulation of physiological force application and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April 5 - 10, 2024 | AACR Annual Meeting April 22 - 23, 2024 | Endocrine Metabolic GPCRs May 13 - 17, 2024

in E. coli-based cell-free and whole cell expression systems A high-throughput structural dynamics approach Meiling Lim TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry NEW April 4 - 7, 2024 | American Physiology Summit April 5 - 10, 2024 | AACR Annual Meeting April 22 - 23, 2024 | Endocrine Metabolic GPCRs May 13 - 17

GPCR Activation and Signaling Neuronal survival factor TAFA2 suppresses apoptosis through binding to Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference NEW April 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 5 - 10, 2024 | AACR Annual Meeting NEW April Development at Department of Drug Design and Pharmacology Faculty of Health and Medical Sciences Octant Apprentice

Class A GPCR GPR3 Antimalarial and Plasmodium falciparum serpentine receptor 12 targeting effect of FDA approved Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways Spliceosome mutations are associated OXER1 antagonists A 19F-qNMR-Guided Mathematical Model for G Protein-Coupled Receptor Signaling Optical Approaches US$3.75 Million Payment in Multi-Target Partnership Sosei Heptares Announces Submission of New Drug Application and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April

Methods & Updates in GPCR Research ThermoBRET: A Ligand-Engagement Nanoscale Thermostability Assay Applied and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April Development at Department of Drug Design and Pharmacology Faculty of Health and Medical Sciences NEW Octant Apprentice

Advantages of targeting GPCRs allosteric sites Allosteric sites offer a more nuanced approach to modulating

Advancements in the use of xenopus oocytes for modelling neurological disease for novel drug discovery Application and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April

and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April

Difficult and Conserved Protein Targets GPCR Therapeutics Expands Pipeline into Fibrosis with a Combination Approach and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April

Financial Results and Exciting Developments at Aelis Farma Ion Channel Drug Developer Maxion Therapeutics Appoints and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April

Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis for acute migraines Addex mGlu2 NAM Cognition Program Receives €4 Million Grant Confo Therapeutics Appoints and Molecular Gating Seminar March 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April

the size of conventional antibodies, makes them highly versatile and easy to manipulate for various applications1,2 All the above lightly represent the potential applications of Nbs to facilitate the development of more